Elevated freight costs due to Red Sea disruption
Freight costs remain elevated due to Red Sea crisis, with an annual burden of ~INR 30 crore impacting other expenses.
medium · management_commentary
Ajanta Pharma Limited — Q2 FY25
Ajanta Pharma delivered a solid Q2 FY25 with revenue of INR 1,187 crore (+15% YoY), driven by strong branded generics growth of 20% (Asia +28%, Africa +35%).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Unpredictable institutional business in Africa
Institutional business (anti-malarial) remains unpredictable due to reliance on procurement agency schedules and funding.
medium · management_commentaryPotential margin pressure from SG&A ramp-up
Analyst raised concern about elevated other expenses; management attributed to SG&A ramp-up and one-time gratuity charge, but H2 expenses expected in line with H1.
low · analyst_questionPrice erosion in US generics
US generics growth remains muted at 2% in H1, with limited launches; pricing pressure and competitive landscape could impact future growth.
medium · data_observation